Fulcrum Therapeutics Stock Price To Book
| FULC Stock | USD 13.00 0.20 1.56% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Fulcrum Therapeutics' long-term financial health and intrinsic value.
As of December 12, 2025, Price To Book Ratio is expected to decline to 1.14. Fulcrum | Price To Book | Build AI portfolio with Fulcrum Stock |
Fulcrum Therapeutics Company Price To Book Analysis
Fulcrum Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Fulcrum Therapeutics Price To Book | 3.77 X |
Most of Fulcrum Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulcrum Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fulcrum Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulcrum Therapeutics is extremely important. It helps to project a fair market value of Fulcrum Stock properly, considering its historical fundamentals such as Price To Book. Since Fulcrum Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulcrum Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulcrum Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Fulcrum Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Fulcrum Therapeutics has a Price To Book of 3.7704 times. This is 85.32% lower than that of the Pharmaceuticals sector and 37.58% lower than that of the Health Care industry. The price to book for all United States stocks is 60.35% higher than that of the company.
Fulcrum Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulcrum Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulcrum Therapeutics could also be used in its relative valuation, which is a method of valuing Fulcrum Therapeutics by comparing valuation metrics of similar companies.Fulcrum Therapeutics is currently under evaluation in price to book category among its peers.
Fulcrum Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fulcrum Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fulcrum Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Fulcrum Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 554.28 M | ||||
| Shares Outstanding | 65.97 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 3.77 X | ||||
| Price To Sales | 5.12 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | (52.4 M) | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 8.63 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.67 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Short Ratio | 4.25 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Price To Earnings To Growth | (0.45) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 3.17 | ||||
| Market Capitalization | 844.42 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
| Net Asset | 260.72 M |
About Fulcrum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulcrum Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulcrum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulcrum Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| PRNEX | T Rowe Price | |
| RPBAX | T Rowe Price | |
| PRDGX | T Rowe Price |
Check out Fulcrum Therapeutics Piotroski F Score and Fulcrum Therapeutics Altman Z Score analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.